Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Clinuvel Pharmaceuticals Limited (AU:CUV)
ASX:CUV
RESEARCH TOOLSreports
Holding AU:CUV?
Track your performance easily
CUV Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$12.96 - AU$18.20
Previous CloseAU$13.16
Volume9.98K
Average Volume (3M)89.37K
Market Cap
AU$658.80M
Enterprise ValueAU$538.55M
Total Cash (Recent Filing)AU$121.51M
Total Debt (Recent Filing)AU$1.26M
Price to Earnings (P/E)18.4
Beta0.32
Next Earnings
Feb 25, 2025EPS Estimate
AU$0.21Last Dividend Ex-Date
Sep 05, 2024Dividend Yield0.38%
Share Statistics
EPS (TTM)0.71
Shares OutstandingN/A
10 Day Avg. Volume74,727
30 Day Avg. Volume89,366
Standard Deviation0.13
R-Squared0.07
Alpha-0.00788
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)15.82
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$26.40Price Target Upside102.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Clinuvel Pharmaceuticals Limited News
PremiumCompany Announcements
Clinuvel Pursues Expanded SCENESSE® Dosage in Europe
PremiumCompany Announcements
Clinuvel Pharmaceuticals Tackles Market Challenges and Opportunities
PremiumCompany Announcements
Clinuvel Pharmaceuticals Refocuses on Core Programs for Growth
PremiumCompany Announcements
Clinuvel Pharmaceuticals Announces Director Change and Shareholdings
PremiumCompany Announcements
Clinuvel Pharmaceuticals Reports Key AGM ResolutionsPremiumCompany Announcements
Clinuvel Pharmaceuticals Faces Challenges Amid Market Dynamics
PremiumCompany Announcements
Clinuvel Pharmaceuticals Pursues Growth with DiversificationPremiumCompany Announcements
Clinuvel Files Compliance Update, Affirms TransparencyOptions Prices
Currently, No data available
---
Ownership Overview
6.87% Insiders
2.68% Mutual Funds
― Other Institutional Investors
87.89% Public Companies and
Individual Investors
CUV FAQ
What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?
Clinuvel Pharmaceuticals Limited lowest share price was AU$12.96 and its highest was AU$18.20 in the past 12 months.
What is Clinuvel Pharmaceuticals Limited’s market cap?
Currently, no data Available
When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?
Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Feb 25, 2025 which is in 94 days.
How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?
Clinuvel Pharmaceuticals Limited released its earnings results on Aug 29, 2024. The company reported AU$0.494 earnings per share for the quarter, beating the consensus estimate of AU$0.441 by AU$0.053.
Is Clinuvel Pharmaceuticals Limited overvalued?
According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued.
Does Clinuvel Pharmaceuticals Limited pay dividends?
Clinuvel Pharmaceuticals Limited pays a Annually dividend of AU$0.05 which represents an annual dividend yield of 0.38%. See more information on Clinuvel Pharmaceuticals Limited dividends here
What is Clinuvel Pharmaceuticals Limited’s EPS estimate?
Clinuvel Pharmaceuticals Limited’s EPS estimate is AU$0.21.
How many shares outstanding does Clinuvel Pharmaceuticals Limited have?
Clinuvel Pharmaceuticals Limited has 50,060,680 shares outstanding.
What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?
Clinuvel Pharmaceuticals Limited reported an EPS of AU$0.494 in its last earnings report, beating expectations of AU$0.441. Following the earnings report the stock price went up 10.863%.
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:CUV
---
Clinuvel Pharmaceuticals Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$26.40 (102.27% Upside)
AU$26.40 (102.27% Upside)
Blogger Sentiment
Bullish
AU:CUV Sentiment 93%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.12%
12-Months-Change
Fundamentals
Return on Equity
19.08%
Trailing 12-Months
Asset Growth
19.70%
Trailing 12-Months
Company Description
Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Ltd. is a global biopharmaceutical company. It engages in the the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
---
CUV Company Deck
---
CUV Earnings Call
Q4 2024
0:00 / 0:00
---
CUV Stock 12 Month Forecast
Average Price Target
AU$26.40
▲(102.27% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Arrowhead Pharmaceuticals
―
Assertio Therapeutics
―
Aurinia Pharmaceuticals
―
Clinuvel Pharmaceuticals Limited
―
Best Analysts Covering CUV
1 Year
1 Year Success Rate
3/15 ratings generated profit
1 Year Average Return
-10.81%
reiterated a buy rating 3 months ago
Copying Melissa Benson's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -10.81% per trade.
---